[go: up one dir, main page]

DE60122175D1 - Chemokin rezeptor bindenden heterozyklischen verbindungen - Google Patents

Chemokin rezeptor bindenden heterozyklischen verbindungen

Info

Publication number
DE60122175D1
DE60122175D1 DE60122175T DE60122175T DE60122175D1 DE 60122175 D1 DE60122175 D1 DE 60122175D1 DE 60122175 T DE60122175 T DE 60122175T DE 60122175 T DE60122175 T DE 60122175T DE 60122175 D1 DE60122175 D1 DE 60122175D1
Authority
DE
Germany
Prior art keywords
receptor binding
heterocyclic compounds
binding heterocyclic
chemokin receptor
chemokin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60122175T
Other languages
English (en)
Other versions
DE60122175T2 (de
Inventor
Gary Bridger
Renato Skerlj
Al Kaller
Curtis Harwig
David Bogucki
R Wilson
Jason Crawford
J Mceachern
Bem Atsma
Siqiao Nan
Yuanxi Zhou
Dominique Schols
Dennis Smith
Fluri Maria Di
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anormed Inc
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Application granted granted Critical
Publication of DE60122175D1 publication Critical patent/DE60122175D1/de
Publication of DE60122175T2 publication Critical patent/DE60122175T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/40Nitrogen atoms attached in position 8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60122175T 2000-09-15 2001-09-17 Chemokinrezeptor bindende heterozyklische Verbindungen Expired - Lifetime DE60122175T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US23289100P 2000-09-15 2000-09-15
US23308700P 2000-09-15 2000-09-15
US233087P 2000-09-15
US232891P 2000-09-15
US23451000P 2000-09-22 2000-09-22
US23481600P 2000-09-22 2000-09-22
US234816P 2000-09-22
US234510P 2000-09-22
PCT/US2001/029590 WO2002034745A1 (en) 2000-09-15 2001-09-17 Chemokine receptor binding heterocyclic compounds

Publications (2)

Publication Number Publication Date
DE60122175D1 true DE60122175D1 (de) 2006-09-21
DE60122175T2 DE60122175T2 (de) 2007-07-05

Family

ID=27499667

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60122175T Expired - Lifetime DE60122175T2 (de) 2000-09-15 2001-09-17 Chemokinrezeptor bindende heterozyklische Verbindungen
DE60143457T Expired - Lifetime DE60143457D1 (de) 2000-09-15 2001-09-17 Chemokin Rezeptor bindende heterozyklische Verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60143457T Expired - Lifetime DE60143457D1 (de) 2000-09-15 2001-09-17 Chemokin Rezeptor bindende heterozyklische Verbindungen

Country Status (16)

Country Link
US (3) US6734191B2 (de)
EP (2) EP1317451B1 (de)
KR (1) KR20030034184A (de)
AT (2) ATE335733T1 (de)
AU (1) AU2001294628B2 (de)
BR (1) BR0113932A (de)
CA (1) CA2421796A1 (de)
DE (2) DE60122175T2 (de)
DK (1) DK1317451T3 (de)
ES (1) ES2269465T3 (de)
HU (1) HUP0302960A3 (de)
IL (1) IL154229A0 (de)
NO (1) NO20031161L (de)
NZ (1) NZ524651A (de)
PT (1) PT1317451E (de)
WO (1) WO2002034745A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000276225B2 (en) * 1999-09-28 2008-07-10 Neurogen Corporation High affinity small molecule C5A receptor modulators
BR0113931A (pt) * 2000-09-15 2004-01-13 Anormed Inc Compostos heterocìclicos ligantes receptores de quimiocinas
ATE404553T1 (de) * 2000-09-29 2008-08-15 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor- modulatoren
CA2425259A1 (en) 2000-10-11 2002-04-18 Tularik, Inc. Modulation of ccr4 function
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
KR20040020075A (ko) 2001-07-31 2004-03-06 아노르메드 인코포레이티드 선조/줄기 세포를 가동시키는 방법
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
AU2002357379A1 (en) 2001-12-21 2003-07-15 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2003265625A1 (en) 2002-08-21 2004-03-11 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
JP3714948B2 (ja) 2002-09-11 2005-11-09 呉羽化学工業株式会社 アミン化合物及びその用途
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
EP1613613B1 (de) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4-chemokinrezeptor-bindende verbindungen
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
AU2004232361A1 (en) 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
RU2228930C1 (ru) * 2003-05-20 2004-05-20 ООО "Исследовательский институт химического разнообразия" Замещенные 3-пиридилметиламины и фокусированная библиотека
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
EP1708703A4 (de) 2003-12-11 2008-04-09 Anormed Inc Chemokin-rezeptor-bindende verbindungen
EP1724263B1 (de) * 2004-03-10 2014-03-05 Kureha Corporation Basische aminverbindung und deren verwendung
RU2006136381A (ru) * 2004-03-15 2008-04-27 Анормед, Инк. (Ca) Способ получения антагониста cxcr4
CA2575560A1 (en) * 2004-08-02 2006-02-23 Smithkline Beecham Corporation Chemical compounds
AU2005272653A1 (en) * 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
CN101039672A (zh) * 2004-08-16 2007-09-19 史密丝克莱恩比彻姆公司 化合物
EP1799671A4 (de) * 2004-09-02 2009-06-10 Smithkline Beecham Corp Chemische verbindungen
EP1793825A4 (de) * 2004-09-24 2009-12-09 Smithkline Beecham Corp Chemische verbindungen
US7790747B2 (en) 2005-06-15 2010-09-07 Genzyme Corporation Chemokine receptor binding compounds
AU2006280945A1 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
PE20070946A1 (es) * 2006-01-25 2007-10-16 Smithkline Beecham Corp COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
CA2659463A1 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
AU2007281677A1 (en) * 2006-08-07 2008-02-14 Genzyme Corporation Combination therapy
WO2009023669A1 (en) * 2007-08-13 2009-02-19 Janssen Pharmaceutica N.V. Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof
EP2227233B1 (de) * 2007-11-30 2013-02-13 Newlink Genetics Ido-inhibitoren
US20150065504A1 (en) 2013-08-21 2015-03-05 Alios Biopharma, Inc. Antiviral compounds
LT3209655T (lt) 2014-10-24 2021-01-11 Landos Biopharma, Inc. Medicininiai preparatai į lantionino sintezę c panašaus baltymo 2 pagrindu
US10933049B2 (en) 2015-06-03 2021-03-02 The University Of Queensland Mobilizing agents and uses therefor
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017112894A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP2019528241A (ja) * 2016-06-16 2019-10-10 サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィクCentre National De La Recherche Scientifique インターフェロンレベルを低下させるのに有用な化合物
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN113748109B (zh) 2019-12-20 2023-07-21 朗多生物制药股份有限公司 羊毛硫氨酸c样蛋白2配体、用所述配体制备的细胞以及使用所述配体的疗法
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス4 ファーマシューティカルズ, インコーポレイテッド 好中球減少症を処置する方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
CA2319781A1 (en) 1998-02-02 1999-08-05 Liping Wang Cyclic amine modulators of chemokine receptor activity
JPH11269146A (ja) 1998-03-24 1999-10-05 Mitsui Chem Inc 分化誘導剤
EP1146790A4 (de) 1999-01-25 2004-03-17 Smithkline Beecham Corp Verbindungen und verfahren
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
WO2000051607A1 (en) * 1999-03-02 2000-09-08 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
IL145401A0 (en) 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
IL154227A0 (en) 2000-09-15 2003-07-31 Anormed Inc Chemokine receptor binding heterocyclic compounds
BR0113931A (pt) * 2000-09-15 2004-01-13 Anormed Inc Compostos heterocìclicos ligantes receptores de quimiocinas
US10468384B2 (en) 2017-09-15 2019-11-05 STATS ChipPAC Pte. Ltd. Semiconductor device and method of forming embedded die substrate, and system-in-package modules with the same

Also Published As

Publication number Publication date
WO2002034745A8 (en) 2003-09-18
US7807694B2 (en) 2010-10-05
EP1752455A2 (de) 2007-02-14
BR0113932A (pt) 2003-06-24
KR20030034184A (ko) 2003-05-01
DE60122175T2 (de) 2007-07-05
US7091217B2 (en) 2006-08-15
EP1752455B1 (de) 2010-11-10
NO20031161D0 (no) 2003-03-13
EP1317451A1 (de) 2003-06-11
EP1752455A3 (de) 2007-02-28
HUP0302960A2 (hu) 2003-12-29
ATE487710T1 (de) 2010-11-15
DE60143457D1 (de) 2010-12-23
AU2001294628B2 (en) 2007-06-07
IL154229A0 (en) 2003-07-31
US20060252795A1 (en) 2006-11-09
DK1317451T3 (da) 2006-12-18
PT1317451E (pt) 2006-12-29
NO20031161L (no) 2003-03-13
HK1059257A1 (en) 2004-06-25
WO2002034745A1 (en) 2002-05-02
ES2269465T3 (es) 2007-04-01
ATE335733T1 (de) 2006-09-15
US6734191B2 (en) 2004-05-11
NZ524651A (en) 2005-08-26
US20040171638A1 (en) 2004-09-02
HUP0302960A3 (en) 2007-03-28
US20030028022A1 (en) 2003-02-06
CA2421796A1 (en) 2002-05-02
EP1317451B1 (de) 2006-08-09

Similar Documents

Publication Publication Date Title
DE60122175D1 (de) Chemokin rezeptor bindenden heterozyklischen verbindungen
DE60137944D1 (de) Chemokin rezeptor bindenden heterozyklische verbindungen
DE60028354D1 (de) Chemokine rezeptor bindende heterozyklische verbindungen
DK1376922T3 (da) Krypteringsindretning
ATE319137T1 (de) Verstärkermodulation
NO20020307D0 (no) N-(indolkarbonyl)piperazinderivater
DE60216693D1 (de) Gerät zum Verteilen von Video und Gerät zum Empfangen von Video
NO20005224D0 (no) BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse
DK1530568T3 (da) Indol- eller benzimidazolderivater til modulering af ikb-kinasen
DE50014679D1 (de) Substituierte indol-mannichbasen
DK1086082T3 (da) Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister
NO20031462D0 (no) Krypteringskommunikasjonssystem
BR0007660B1 (pt) dispositivo tensor.
DE60021170D1 (de) Verstärker
ITMI20021403A0 (it) Sistema per autenticazione mutua protetta
FI19992595L (fi) Tilaajalaitteen autentikointi
DE60038911D1 (de) 4-Phenylpiperazinyl, -piperidinyl und -tetrahydropyridyl-Derivate als Dopamin D4-Antagonisten
DE60201856D1 (de) Klasse-D Verstärker
SE0102384D0 (sv) New compounds
ATE264301T1 (de) Muscarin-antagonisten
DE60045575D1 (de) Verstärker
DE50003014D1 (de) N-substituierte perhydrodiazine
DK1374238T3 (da) Optagelsesbærer og enhed til scanning af optagelsesbæreren
DE60001002D1 (de) Kommunikationsanlage zum gemeinsamen empfang von informationen
DZ3193A1 (fr) Méthode d'encryptage multi-modules.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition